Forge Biologics adds Duke University School of Medicine as a Clinical Trial Site for Krabbe disease
COLUMBUS, OHIO June 26, 2024 – Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced that it has added the Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine, as a clinical trialA clinical trial is research designed to understand the safety and efficacy of a drug, biologic or device. There are 4 phases to most clinical trials from Phase 1 that seeks to answer safety concern site for its REKLAIM trial with Dr. Joanne Kurtzberg as acting Principal Investigator (PI). The other site for this clinical trial is the University of Michigan Hospital. The Orange County Children’s Hospital will no longer see new patients. KrabbeConnect invites you to read the full press release here.